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latelet concentrates from ABO-identical donors are the com-
onents of choice for transfusions. Since platelet inventories
re generally insufﬁcient and because there is usually a higher
requency of group O donors, perfect matches are not always
ossible and therefore ABO-incompatible platelet transfu-
ions are an accepted practice when ABO-identical platelets
re unavailable.1 However, an acute hemolytic transfusion
eaction (HTR) can be a severe complication after this type
f transfusion due to the passive transfusion of antibodies
rom donors possessing unusually high-titers of anti-A and/or
nti-B antibodies.2
Reducing the risk of HTRs due to plasma-incompatible
latelet transfusions has been generating interest and dis-
ussions. Strategies to reduce the risk of platelet-associated
TRs include volume reduction of platelets and screening
onor plasma for high titers of antibodies by performing anti-
 and/or anti-B titration or assays for in vitro hemolysis.1Methods currently employed to identify high titers of anti-
 and/or anti-B antibodies include titration by the saline
gglutination test, with and without incubation, gel test,
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eserved.solid-phase test, ﬂow cytometry, automated technologies and
a qualitative hemolysin test. Many countries have adopted
universal screening where a critical IgM titer is between 64
and 100 in tube or gel tests, and a critical IgG titer is between
200 and 512.3,4 However, non-standardized methods of IgM or
IgG isohemagglutinin titration and the lack of agreement of
a ‘critical titer’ that will predict in vivo hemolysis have made
the determination of ABO antibody titers difﬁcult and limited
to a few blood banks.5 Additionally, documentation that titer
methods prevent HTRs is not clear. Based on this, it remains
unclear whether titration is the best or most cost–effective
approach. Currently, the use of the hemolysin test for the
identiﬁcation of hemolytic anti-A and anti-B antibodies has
emerged as a useful screening test to identify high levels of
anti-A and/or anti-B antibodies and has recently been sug-
gested by the Brazilian legislation as prophylaxis for acutee Estadual de Campinas (Unicamp), Rua Carlos Chagas 480, Barão
Regulatory agencies require that blood banks have a policy
to prevent HTRs due to plasma-incompatible platelet trans-
fusions but the choice of the best approach to predict HTRs
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is still a big challenge as little is known about the correlation
between isohemagglutinin titration and the hemolysin test,
and the impact of each test on the prevention of hemolysis
and on platelet inventory management.
In this issue, there is an important study on the correla-
tion between isohemagglutinin titration and the qualitative
hemolysin test as prophylactic tests to prevent HTRs.6 The
authors evaluated the impact of each prophylaxis on platelet
inventory management and the ability of the hemolysin test
to avoid red blood cell (RBC) sensitization after the transfusion
of incompatible units.6 In this study, they demonstrate that
the results of isohemagglutinin titration are not related to the
results of the hemolysin qualitative test and the absence of
hemolysis does not prevent RBC sensitization. They also con-
clude that the implementation of the hemolysin test as the
prophylaxis of choice for hemolysis signiﬁcantly affects the
platelet inventory management. Therefore, according to the
authors, isohemagglutinin titration using a well-standardized
method determining a cut-off for labeling a product as high-
titer is still the best approach.
This paper represents an additional contribution for
designing and implementing policies to improve the safety
of ABO-incompatible platelet transfusions. The results of the
studies by Landim et al.6 also show that no standard strategy
exists to mitigate in vivo hemolysis and serve to stimulate a
review of Brazilian practices and policies for the advancement
of platelet transfusion safety.
The ﬁnding that none of the methods (isohemagglutinin
titration and the hemolysin test) is guaranteed to eliminate
the risk of passive hemolysis supports the concept that there
are combinations of factors inﬂuencing hemolysis due to
plasma-incompatible platelets.3 2 0 1 5;3  7(4):215–216
Although HTR after ABO-incompatible platelet transfu-
sions is a rare event we will have to look to future studies
to better understand other risk factors in addition to the best
cut-off for ABO plasma-incompatible titers.
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